By Mayo Clinic –
A Mayo Clinic study published in the September 2025 issue of Science Advances explores a novel approach to retinal gene therapy using fibrin hydrogels encapsulating adeno-associated virus 2-green fluorescent protein (AAV2-GFP). The findings suggest a promising, less invasive alternative for the treatment of blinding retinal diseases. Luxturna was approved by the Food and Drug Administration in 2017 for RPE65-related inherited retinal dystrophy and was the first in vivo gene therapy.
